Learn More About TROGARZO®

Access the following resources to learn more about TROGARZO® and the THERA patient support® Program.


The Discussion Guide can help you start the conversation with your healthcare provider about TROGARZO®.



Learn more about support available while taking TROGARZO®.


“I’ve seen my viral load improve, as well as my overall health!”

Jason’s Experience*

Watch a real patient tell their TROGARZO® story

*Jason received his TROGARZO® doses via IV infusion prior to the approval of IV push administration and has been compensated for his time.


  1. TROGARZO® Prescribing Information. Theratechnologies Inc. December 2023.
  2. TROGARZO® Prescribing Information Patient Leaflet. Theratechnologies Inc. December 2023.
  3. Beesley B et al. Real‑world HIV patient experience with long‑acting ibalizumab. ACTHIV 2021 poster #P-23.
  4. TROGARZO® Patient Satisfaction Study. March 22, 2021.
  5. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV (March, 2023). Department of Health and Human Services. Available at: https://clinicalinfo.hiv.gov/sites/default/files/guidelines/documents/adult-adolescent-arv/guidelines-adult-adolescent-arv.pdf.

Important Safety Information

The most common side effects of TROGARZO® include diarrhea, dizziness, nausea, and rash. These are not all the possible side effects of TROGARZO®. For complete important safety information, please click here.

Important Safety Information

TROGARZO® (ibalizumab‑uiyk) is a prescription medicine that is used with other antiretroviral medicines to treat Human Immunodeficiency Virus‑1 (HIV‑1) infection in adults who:

  • have received anti‑HIV‑1 regimens in the past, and
  • have HIV‑1 virus that is resistant to many antiretroviral medicines, and
  • who are failing their current antiretroviral therapy

It is not known if TROGARZO® is safe and effective in children.

Before you receive TROGARZO® (ibalizumab‑uiyk), tell your healthcare provider about all of your medical conditions, including if you are:

  • Pregnant or plan to become pregnant. It is not known if TROGARZO® may harm your unborn baby. Tell your healthcare provider if you become pregnant during treatment with TROGARZO®.
  • Pregnancy Registry: There is a pregnancy registry for women who take antiretroviral medicines during pregnancy. The purpose of this registry is to collect information about the health of you and your baby. Talk with your healthcare provider about how you can take part in this registry.
  • Breastfeeding or plan to breastfeed. You should not breastfeed if you have HIV‑1 because of the risk of passing HIV‑1 to your baby. Do not breastfeed if you are receiving TROGARZO® as it is not known if TROGARZO® passes into breast milk. Talk with your healthcare provider about the best way to feed your baby during treatment with TROGARZO®.

Tell your healthcare provider about all the medicines you take, including prescription and over‑the‑counter medicines, vitamins, and herbal supplements.

TROGARZO® can cause serious side effects, including:

  • Allergic reactions. TROGARZO® can cause allergic reactions, including serious reactions, during and after infusion. Tell your healthcare provider or nurse, or get medical help right away if you get any of the following symptoms of an allergic reaction: trouble breathing, swelling in your throat, wheezing, chest pain, chest tightness, cough, hot flush, nausea or vomiting.
  • Changes in your immune system (Immune Reconstitution Inflammatory Syndrome) can happen when you start taking HIV‑1 medicines. Your immune system might get stronger and begin to fight infections that have been hidden in your body for a long time. Tell your healthcare provider right away if you start having new symptoms after receiving TROGARZO®.
  • The most common side effects of TROGARZO® include diarrhea, dizziness, nausea, and rash. These are not all the possible side effects of TROGARZO®.

For more information or medical advice about side effects, ask your healthcare provider. You may report side effects to the FDA at 1‑800‑FDA-1088 or the THERA patient support® Program at 1‑833‑238-4372.

Please see Important Safety Information throughout or access the full Prescribing Information for TROGARZO® online at www.trogarzo.com.